vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and Valneva SE (VALN), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Valneva SE is the larger business by last-quarter revenue ($36.2M vs $8.1M, roughly 4.5× Cellectis S.A.). Valneva SE runs the higher net margin — -313.5% vs -54.1%, a 259.4% gap on every dollar of revenue.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.
CLLS vs VALN — Head-to-Head
Income Statement — Q2 2024 vs Q1 2023
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $36.2M |
| Net Profit | $-25.3M | $-19.6M |
| Gross Margin | — | 38.9% |
| Operating Margin | -213.5% | -49.5% |
| Net Margin | -313.5% | -54.1% |
| Revenue YoY | 4428.7% | — |
| Net Profit YoY | -51.9% | — |
| EPS (diluted) | $-0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q2 24 | $8.1M | — | ||
| Q2 23 | $178.0K | — | ||
| Q1 23 | — | $36.2M | ||
| Q2 22 | $1.3M | $93.2M |
| Q2 24 | $-25.3M | — | ||
| Q2 23 | $-16.6M | — | ||
| Q1 23 | — | $-19.6M | ||
| Q2 22 | $-19.5M | — |
| Q2 24 | — | — | ||
| Q2 23 | 69.1% | — | ||
| Q1 23 | — | 38.9% | ||
| Q2 22 | 74.8% | — |
| Q2 24 | -213.5% | — | ||
| Q2 23 | -13270.2% | — | ||
| Q1 23 | — | -49.5% | ||
| Q2 22 | -2089.7% | -161.3% |
| Q2 24 | -313.5% | — | ||
| Q2 23 | -9348.9% | — | ||
| Q1 23 | — | -54.1% | ||
| Q2 22 | -1488.4% | — |
| Q2 24 | $-0.28 | — | ||
| Q2 23 | $-0.20 | — | ||
| Q1 23 | — | — | ||
| Q2 22 | $-0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $221.2M |
| Total Assets | $407.1M | $637.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q2 24 | $149.0M | — | ||
| Q2 23 | $84.4M | — | ||
| Q1 23 | — | $274.8M | ||
| Q2 22 | $129.4M | $363.1M |
| Q2 24 | $148.6M | — | ||
| Q2 23 | $96.6M | — | ||
| Q1 23 | — | $221.2M | ||
| Q2 22 | $180.5M | $100.7M |
| Q2 24 | $407.1M | — | ||
| Q2 23 | $227.7M | — | ||
| Q1 23 | — | $637.2M | ||
| Q2 22 | $320.9M | $783.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-26.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | — | — |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | $-26.3M | ||
| Q2 22 | — | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.